US Pharma MarketingRoivant reports Phase 2 win for lung disease drug that it got from Bayer
Roivant Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in vivo therapies Drug pricing and the IRA: Tracking the government's negotiation power FDA policy and drug approvals: What’s changing…
Roivant Sciences said Tuesday its inhaled drug candidate has passed a mid-stage test in interstitial lung disease, surpassing Wall Street’s benchmarks for success.
In the Phase 2 trial, mosliciguat met the primary endpoint of change ...
Source: Endpoints News